L-Tryptophan Encyclopedia — Scientific Background

What Is L-Tryptophan?

L-Tryptophan (CAS 73-22-3), also known as (2S)-2-amino-3-(1H-indol-3-yl)propanoic acid or L-2-amino-3-indolylpropanoic acid, is an essential proteinogenic aromatic amino acid with the molecular formula C₁₁H₁₂N₂O₂ and a molecular weight of 204.23 g/mol. It occurs as a white to off-white crystalline powder with a slightly bitter taste, and has a water solubility of 11.4 g/L at 25°C. L-Tryptophan is one of the nine essential amino acids in humans and is the least abundant of the essential amino acids in most dietary proteins.

Metabolic Pathways and Physiological Functions

Serotonin and Melatonin Biosynthesis

L-Tryptophan is the sole dietary precursor to serotonin (5-hydroxytryptamine, 5-HT). The biosynthesis pathway begins with the hydroxylation of L-tryptophan to 5-hydroxytryptophan (5-HTP) by the enzyme tryptophan hydroxylase (TPH), which is the rate-limiting step in serotonin synthesis. 5-HTP is then rapidly decarboxylated to serotonin by aromatic L-amino acid decarboxylase. Serotonin is subsequently converted to N-acetylserotonin by serotonin N-acetyltransferase and then to melatonin by hydroxyindole-O-methyltransferase in the pineal gland. Approximately 95% of dietary tryptophan is metabolized through the kynurenine pathway, while only about 1–2% is converted to serotonin in the brain.

The Kynurenine Pathway

The kynurenine pathway is the primary route of tryptophan metabolism, accounting for approximately 95% of dietary tryptophan degradation. This pathway produces several neuroactive metabolites, including kynurenic acid (neuroprotective) and quinolinic acid (neurotoxic), and also generates NAD⁺ as a cofactor. The balance between the serotonin and kynurenine pathways is influenced by immune activation, stress, and micronutrient status.

Niacin (Vitamin B3) Synthesis

L-Tryptophan is a precursor for the biosynthesis of niacin (vitamin B3) in the liver. Approximately 60 mg of dietary tryptophan is equivalent to 1 mg of niacin in humans.

Clinical Evidence

Sleep Quality — Systematic Review and Meta-Analysis

A systematic review, meta-analysis, and meta-regression published in Nutrition Reviews (2022) evaluated the impact of tryptophan supplementation on sleep quality. The study reviewed randomized controlled trials and found that tryptophan supplementation significantly improved sleep quality parameters, including sleep latency, sleep efficiency, and subjective sleep satisfaction. The review concluded that tryptophan supplementation may be beneficial for improving sleep quality.

Depression and Mood — Cochrane Review

A Cochrane review considered 111 trials to determine whether 5-HTP and tryptophan were more effective than placebo and whether they were safe to treat depressive disorders in adults. Only two trials were considered of sufficient quality to meet inclusion criteria. The study by Thomson et al. tested L-tryptophan in 28 patients with mild depression and 26 controls. The patients with depression were given placebo for 1 week followed by 12 weeks of L-tryptophan (1 g three times daily), with the 26 controls given placebo for 13 weeks. Both preparations showed superiority to placebo in alleviating depression. While four patients receiving active treatments reported side effects (i.e., dizziness, nausea and diarrhoea), no side effects were reported in the placebo group.

Major Depressive Disorder — Randomized Controlled Trial

A preliminary randomized double-blind placebo-controlled trial evaluated the combination of tryptophan with fluoxetine to treat major depressive disorder. The study demonstrated that combining 20 mg of fluoxetine with 2 g of tryptophan daily at the outset of treatment appears to be a safe protocol that may have both a rapid antidepressant effect and a protective effect on slow-wave sleep.

Seasonal Affective Disorder

Preliminary findings support that combining 1 to 3 g per day of L-tryptophan and early-morning bright light exposure is more efficacious than either treatment alone in patients diagnosed with seasonal affective disorder. No cases of serotonin syndrome or other serious adverse effects were reported with these doses.

Dietary Tryptophan and Mood

A randomized controlled trial published in PubMed (2014) evaluated the effects of dietary tryptophan on affective disorders. A within-subjects analysis indicated significantly (p<.01) more positive affect scores after consuming a high-tryptophan diet as compared to a low-tryptophan diet. Consuming more dietary tryptophan resulted in (p<.05) less depressive symptoms and decreased anxiety.

Cognitive Function — Randomized Controlled Trial

A randomized, double-blinded, placebo-controlled crossover study with 77 healthy adults challenged with an acute 200-mg 5-HTP intake and a 4-week diet containing 500 mg Trp/d showed that 5-HTP or Trp may positively influence the recognition of positive emotions and better integration of information.

Liposomal L-tryptophan

liposomal encapsulation of L-tryptophan provides a fundamentally different delivery mechanism from conventional forms. The phospholipid bilayer surrounds the L-tryptophan molecule, forming a protective shell that enhances stability, absorption, and cellular uptake. This delivery system:

• Achieves approximately 80% retention after 24 hours, compared to only 20% for formulations with lower encapsulation efficiency

• Protects L-tryptophan from premature metabolism in the gastrointestinal tract

• Bypasses the competitive LNAA transport pathway

• Provides sustained release for balanced serotonin support

• Demonstrates low cytotoxic effects (maximum 30% cell death) in Caco-2 studies

Polymerized liposomes were obtained by UV irradiation of vesicles containing 1,2-bis(10,12-tricosadivnoyl)-sn-glycero-3-phosphocholine and 1,2-dimyristoyl-sn-glycero-3-phosphocholine in a 1:1 molar ratio, in the presence of 10 and 50 mol% of L-tryptophan. High L-tryptophan concentrations (50 mol% relative to total lipid concentration) induced a higher amount of six- and nine-unit polymers, responsible for better accommodation of the polar head region. Polymerized liposomes with 50 mol% of L-tryptophan were able to retain around 80% of the amino acid after 24 hours, whereas those with 10 mol% were able to retain 20%. Cytotoxic effects were low in the presence of polymerized liposomes, rendering a maximum percentage of cell death of 30% in Caco-2 studies. The absence of significant cytotoxic effects allows the system proposed to be applied in human health.

Safety and Regulatory

L-Tryptophan is generally well tolerated at commonly used doses. A Cochrane review noted that only relatively minor side effects were reported from the ingestion of L-tryptophan, including dizziness, nausea, and diarrhoea. A within-subjects analysis of high-tryptophan diets showed significantly more positive affect scores and less depressive symptoms compared to low-tryptophan diets, with no serious adverse effects reported.

Historical Safety Context: The historical association of L-tryptophan with eosinophilia-myalgia syndrome (EMS) in the late 1980s was linked to a contaminant in a specific production batch from a single manufacturer. Subsequent investigations indicated that the toxic effect reflected a contaminant in that particular production batch, and pure pharmaceutical-grade L-tryptophan did not appear to have this effect. The FDA banned the importation of L-Trp in March 1990, and with the imported amino acid no longer available in the marketplace, the incidence of EMS rapidly declined. Modern L-tryptophan production must conform to European Pharmacopoeia specifications regarding impurity limits. L-Tryptophan is Generally Recognized As Safe (GRAS) by the FDA for use as a nutrient supplement in food and dietary supplements.

Regulatory Status:

• United States — L-Tryptophan is regulated as a dietary supplement ingredient and is Generally Recognized As Safe (GRAS) for use in food and dietary supplements. It is listed in the FDA 'Substances Added to Food' inventory (formerly EAFUS).

• European Union — The AESAN has recommended a maximum daily amount of 220 mg/day of L-tryptophan in food supplements. The UK Committee on the Toxicity of Chemicals in Food, Consumer Products and the Environment (COT) proposed a guidance level of 220 mg/day for L-tryptophan intake, provided that the L-tryptophan used conforms to European Pharmacopoeia specifications.

• Global Standards — L-Tryptophan is monographed in the USP, European Pharmacopoeia, and Japanese Pharmacopoeia, with an assay specification of 98.5%–101.5% on dried basis.

Drug Interactions: L-Tryptophan should not be taken with monoamine oxidase inhibitors (MAOIs), SSRIs, or other serotonergic drugs without medical supervision due to the theoretical risk of serotonin syndrome. The serotonin syndrome has been reported in patients taking L-tryptophan and fluoxetine together. 5-HTP monotherapy or in combination with other antidepressant medication therapy (at least in dosages less than 50 mg/kg) has not been reported to result in a serotonin syndrome.

Testing protocols must adhere to international standards including USP, European Pharmacopoeia, and FAO/WHO Codex Alimentarius. Formulators should verify local regulatory requirements prior to market entry.

This product is intended for research, nutraceutical, and functional food applications. Not intended to diagnose, treat, cure, or prevent any disease.

99$/KG